Multikinase Inhibitors in Metastatic Renal Cell Carcinoma: Indirect Comparison Meta-Analysis

Clinical Therapeutics

Volumn 33, Issue 6, 2011, Pages 708-716

  Leung, Henry W C ^a   Chan, Agnes L F ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Metastatic renal cell carcinoma; Multikinase inhibitors; Progression free survival

Indexed keywords

ALPHA INTERFERON; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB;

CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COMPARATIVE STUDY; DATA EXTRACTION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; EMBASE; FATIGUE; HAND FOOT SYNDROME; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MEDLINE; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 79959423688     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.003     Document Type: Review

References (22)

1. SEER Stat Fact Sheets: Kidney and Renal Pelvis National Cancer Institute, Accessed August 2010. http://seer.cancer.gov/statfacts/html/kidrp.html.
2. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance TA 169 March 2009, National Institute for Health and Clinical Excellence, Accessed May 9, 2011. http://guidance.nice.org.uk/TA169.
3. Ljungberg B.Hanbury D.C., Kuczyk M.A., et al. Renal cell carcinoma guideline. Eur Urol 2007, 51:1502-1510.
4. Taiwan Cancer Registry, Accessed May 9, 2011. http://www.mc.ntu.edu.tw/CRS/main.php?Page=A5.
5. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance 178 National Institute for Health and Clinical Excellence, Accessed May 6, 2011. http://www.nice.org.uk/nicemedia/pdf/TA178Guidance1.pdf.
6. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. TARGET Study Group.
7. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289.
8. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
9. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
10. Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
11. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
12. Schwenk W., Haase O., Günther N., Neudecker J. Methodological quality of randomised controlled trials comparing short-term results of laparoscopic and conventional colorectal resection. Int J Colorectal Dis 2007, 22:1369-1376.
13. Spruance S.L., Reid J.E., Grace M., Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004, 48:2787-2792.
14. Fleiss J.L. The statistical basis of meta-analysis. Stats Methods Med Res 1993, 2:121-145.
15. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
16. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
17. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
18. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
19. Renal cell carcinoma nomogram Memorial Sloan-Kettering Cancer Center, Accessed May 9, 2011. http://www.mskcc.org/mskcc/html/6156.cfm.
20. Mills E.J., Rachlis B., O'Regan C., et al. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009, 9:34.
21. Escudier B., Albiges L., Blesius A., et al. How to select targeted therapy in renal cell cancer. Ann Oncol 2010, 21(Suppl 7):vii59-vii62.
22. Leibovich B.C., Cheville J.C., Lohse C.M., et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005, 174:1759-1763.